ArticleBioMed research international2020
Effects of Nintedanib in an Animal Model of Liver Fibrosis.
Article in BioMed research international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 28 citations in OpenAlex.
- Prevent or Treat? Evaluating a Delayed Treatment With Nintedanib After Murine Orthotopic Tracheal Transplantation.Transplantation direct · 2026Article
- Prophylactic Effects of Combined Bosentan and Nintedanib on Early Post-Traumatic Joint Contracture Formation in a Rat Model.Journal of clinical medicine · 2026Article
- Fibrotic remodeling in the NOD/ShiLtJ mouse model of Sjögren's disease: insights from single-cell transcriptomics and AI-driven ECM quantification.Frontiers in immunology · 2026Article
- The intersection of liver cirrhosis and pulmonary fibrosis.Journal of translational medicine · 2025Review
- In Vivo Target Engagement Assessment of Nintedanib in a Double-Hit Bleomycin Lung Fibrosis Rat Model.International journal of molecular sciences · 2025Article
- Effects of antifibrotic agent Nintedanib on experimentally generated priapism model in rats.World journal of urology · 2025Article
- M2 Macrophages-Based Immunotherapy: A New Therapeutic Approach in Liver Fibrosis.Advanced pharmaceutical bulletin · 2025Review
- A protective role of nintedanib in peritoneal fibrosis through H19-EZH2-KLF2 axis via impeding mesothelial-to-mesenchymal transition.International urology and nephrology · 2024Article
- Recent Advances in Research on Active Compounds Against Hepatic Fibrosis.Current medicinal chemistry · 2024Review
- Exploring skeletal muscle tolerance and whole-body metabolic effects of FDA-approved drugs in a volumetric muscle loss model.Physiological reports · 2023Article
- Mechanisms of Yajieshaba in the treatment of liver fibrosis through the Keap1-Nrf2 signaling pathway.Frontiers in pharmacology · 2023Article
- Saracatinib, a Selective Src Kinase Inhibitor, Blocks Fibrotic Responses in Preclinical Models of Pulmonary Fibrosis.American journal of respiratory and critical care medicine · 2022Article
- Targeting HSP47 and HSP70: promising therapeutic approaches in liver fibrosis management.Journal of translational medicine · 2022Review
- Delayed Administration of Nintedanib Ameliorates Fibrosis Progression in CG-Induced Peritoneal Fibrosis Mouse Model.Kidney diseases (Basel, Switzerland) · 2022Article
- Anti-fibrotic effects of pharmacologic FGF-2: a review of recent literature.Journal of molecular medicine (Berlin, Germany) · 2022Review
- The anti-fibrotic agent nintedanib protects chondrocytes against tumor necrosis factor-ɑ (TNF-ɑ)-induced extracellular matrix degradation.Bioengineered · 2022Article
- Nintedanib induces gene expression changes in the lung of induced-rheumatoid arthritis-associated interstitial lung disease mice.PloS one · 2022Article
- The tyrosine-kinase inhibitor Nintedanib ameliorates autosomal-dominant polycystic kidney disease.Cell death & disease · 2021Article
- Extracellular matrix and Hippo signaling as therapeutic targets of antifibrotic compounds for uterine fibroids.Clinical and translational medicine · 2021Article
- Targeting the tumor microenvironment in cholangiocarcinoma: implications for therapy.Expert opinion on investigational drugs · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic sclerosis can affect multiple internal organs, including the liver and lungs. Nintedanib, an antifibrotic approved for treatment of interstitial lung disease associated with systemic sclerosis, may have activity outside of the lungs. This study explored the effect of preventive and therapeutic nintedanib treatment in a 3-week carbon tetrachloride (CCL
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.